Download PDF
Semin Thromb Hemost 2010; 36(5): 477-484
DOI: 10.1055/s-0030-1255441
© Thieme Medical Publishers

Topical Recombinant Human Thrombin in Surgical Hemostasis

Lyndsey J. Bowman1 , Christopher D. Anderson2 , William C. Chapman2 , 3
  • 1Kidney and Liver Transplantation, Barnes-Jewish Hospital, St. Louis, Missouri
  • 2Section of Abdominal Transplantation, St. Louis, Missouri
  • 3Division of General Surgery, Washington University in St. Louis, St. Louis, Missouri
Further Information

Publication History

Publication Date:
14 July 2010 (online)

    Permissions and Reprints

ABSTRACT

The achievement of hemostasis is paramount, and good operative practice is crucial to all surgical procedures. Intraoperative hemostasis is usually achieved through suture ligation for larger vessels and electrocautery of smaller vessels; certain cases, however, are not amenable to these techniques, especially when there is diffuse raw surface bleeding. When operative hemorrhage exists despite appropriate preventive actions and good surgical technique, additional methods for controlling intra- and perioperative hemorrhage should be considered, and may include the use of topical thrombin. Recombinant human thrombin (rhThrombin) was approved by the Food and Drug Administration in 2008, with the expectation of overcoming the disadvantages of previously available topical thrombin preparations. The efficacy of rhThrombin has been demonstrated in three randomized controlled trials and found to be effective for achieving hemostasis within 10 minutes of administration for mild to moderate diffuse raw surface bleeding. rhThrombin is equally as effective as bovine thrombin, with a significantly lower risk of immunogenicity. Similar economic parameters, efficacy, and safety profiles between rhThrombin and other available thrombin preparations may support its use over other bovine- and plasma-derived human thrombin products and carry limited to no risk of viral transmission or development of antithrombin antibodies.

KEYWORDS

Topical - recombinant thrombin - hemostasis - antithrombin antibodies - thrombin

REFERENCES

  • 1 2006 National Hospital Discharge Survey. Hyattsville, MD; National Center for Health Statistics Available at: http://www.cdc.gov/nchs/fastats/insurg.htm Accessed December 1, 2009
    Google Scholar
  • 2 Shander A. Financial and clinical outcomes associated with surgical bleeding complications.  Surgery. 2007;  142(4, Suppl) S20-S25
    CrossrefPubMedGoogle Scholar
  • 3 Lynn M, Jeroukhimov I, Klein Y, Martinowitz U. Updates in the management of severe coagulopathy in trauma patients.  Intensive Care Med. 2002;  28(suppl 2) S241-S247
    CrossrefPubMedGoogle Scholar
  • 4 Dorion R P, Hamati H F, Landis B, Frey C, Heydt D, Carey D. Risk and clinical significance of developing antibodies induced by topical thrombin preparations.  Arch Pathol Lab Med. 1998;  122(10) 887-894
    PubMedGoogle Scholar
  • 5 Carroll J F, Moskowitz K A, Edwards N M, Hickey T J, Rose E A, Budzynski A Z. Immunologic assessment of patients treated with bovine fibrin as a hemostatic agent.  , [see comment] Thromb Haemost. 1996;  76(6) 925-931
    PubMedGoogle Scholar
  • 6 Ortel T L, Mercer M C, Thames E H, Moore K D, Lawson J H. Immunologic impact and clinical outcomes after surgical exposure to bovine thrombin.  Ann Surg. 2001;  233(1) 88-96
    CrossrefPubMedGoogle Scholar
  • 7 Streiff M B, Ness P M. Acquired FV inhibitors: a needless iatrogenic complication of bovine thrombin exposure.  Transfusion. 2002;  42(1) 18-26
    CrossrefPubMedGoogle Scholar
  • 8 Thrombin-JMI [package insert]. King Pharmaceuticals, Inc November 2007
    Google Scholar
  • 9 Lawson J H. The clinical use and immunologic impact of thrombin in surgery.  Semin Thromb Hemost. 2006;  32(Suppl 1) 98-110
    Article in Thieme ConnectPubMedGoogle Scholar
  • 10 EVITHROM [package insert]. OMRIX Biopharmaceuticals Ltd September 2007
    Google Scholar
  • 11 Doria C, Fischer C P, Wood C G, Li P M, Marra S, Hart J. Phase 3, randomized, double-blind study of plasma-derived human thrombin versus bovine thrombin in achieving hemostasis in patients undergoing surgery.  Curr Med Res Opin. 2008;  24(3) 785-794
    CrossrefPubMedGoogle Scholar
  • 12 RECOTHROM [package insert]. ZymoGenetics, Inc Seattle, WA; 2009
    Google Scholar
  • 13 Hoffman M, Monroe III D M. A cell-based model of hemostasis.  Thromb Haemost. 2001;  85(6) 958-965
    PubMedGoogle Scholar
  • 14 Bishop P D, Lewis K B, Schultz J, Walker K M. Comparison of recombinant human thrombin and plasma-derived human alpha-thrombin.  Semin Thromb Hemost. 2006;  32(Suppl 1) 86-97
    Article in Thieme ConnectPubMedGoogle Scholar
  • 15 Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research .In: Pharmacology/Toxicology Review Memorandum. BLA 125248 Thrombin (Recombinant); 2007. Accessed Available at: http://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/ucm120589.pdf Accessed October 5, 2009
    PubMedGoogle Scholar
  • 16 Weaver F A, Lew W, Granke K, Yonehiro L, Delange B, Alexander W A. Study Investigators . A comparison of recombinant thrombin to bovine thrombin as a hemostatic ancillary in patients undergoing peripheral arterial bypass and arteriovenous graft procedures.  J Vasc Surg. 2008;  47(6) 1266-1273
    CrossrefPubMedGoogle Scholar
  • 17 Chapman W C, Lockstadt H, Singla N, Kafie F E, Lawson J H. Phase 2, randomized, double-blind, placebo-controlled, multicenter clinical evaluation of recombinant human thrombin in multiple surgical indications.  J Thromb Haemost. 2006;  4(9) 2083-2085
    CrossrefPubMedGoogle Scholar
  • 18 Chapman W C, Singla N, Genyk Y et al.. A phase 3, randomized, double-blind comparative study of the efficacy and safety of topical recombinant human thrombin and bovine thrombin in surgical hemostasis [see comment].  J Am Coll Surg. 2007;  205(2) 256-265
    CrossrefPubMedGoogle Scholar
  • 19 Hughes S D, Bishop P D, Garcia R, Zhang T, Alexander W A. Topical recombinant thrombin at a concentration of 1000 IU/mL reliably shortens in vivo TTH and delivers durable hemostasis in the presence of heparin anticoagulation and clopidogrel platelet inhibition in a rabbit model of vascular bleeding.  Ann Surg Innov Res. 2009;  3 14
    CrossrefPubMedGoogle Scholar
  • 20 Greenhalgh D G, Gamelli R L, Collins J et al.. Recombinant thrombin: safety and immunogenicity in burn wound excision and grafting.  J Burn Care Res. 2009;  30(3) 371-379
    CrossrefPubMedGoogle Scholar
  • 21 Heffernan J K, Ponce R A, Zuckerman L A et al.. Preclinical safety of recombinant human thrombin.  Regul Toxicol Pharmacol. 2007;  47(1) 48-58
    CrossrefPubMedGoogle Scholar
  • 22 Whitaker A N, McKay D G. Induction of hypotension in rhesus monkeys and rabbits by intravenous thrombin infusion.  Lab Invest. 1969;  20(1) 79-86
    PubMedGoogle Scholar
  • 23 Gershon S K, Chang A C, Purvis W V, Salive M. Misadministration of topical bovine thrombin.  JAMA. 1999;  282(20) 1919
    CrossrefPubMedGoogle Scholar
  • 24 Cicala C, Bucci M, De Dominicis G, Harriot P, Sorrentino L, Cirino G. Bronchoconstrictor effect of thrombin and thrombin receptor activating peptide in guinea-pigs in vivo.  Br J Pharmacol. 1999;  126(2) 478-484
    CrossrefPubMedGoogle Scholar
  • 25 Uchigasaki S, Takahashi H, Suzuki T. A case of delayed death after accidental intravenous injection of thrombin.  Int J Legal Med. 1998;  111(4) 202-204
    CrossrefPubMedGoogle Scholar
  • 26 Pusateri A E, Holcomb J B, Bhattacharyya S N et al.. Different hypotensive responses to intravenous bovine and human thrombin preparations in swine.  J Trauma. 2001;  50(1) 83-90
    CrossrefPubMedGoogle Scholar
  • 27 Ofosu F A, Crean S, Reynolds M W. A safety review of topical bovine thrombin-induced generation of antibodies to bovine proteins.  Clin Ther. 2009;  31(4) 679-691
    CrossrefPubMedGoogle Scholar
  • 28 Nelsestuen G L, Suttie J W. The carbohydrate of bovine prothrombin. Partial structural determination demonstrating the presence of -galactose residues.  J Biol Chem. 1972;  247(19) 6096-6102
    PubMedGoogle Scholar
  • 29 Mizuochi T, Yamashita K, Fujikawa K, Kisiel W, Kobata A. The carbohydrate of bovine prothrombin. Occurrence of Gal beta 1 leads to 3GlcNAc grouping in asparagine-linked sugar chains.  J Biol Chem. 1979;  254(14) 6419-6425
    PubMedGoogle Scholar
  • 30 Nilsson B, Horne III M K, Gralnick H R. The carbohydrate of human thrombin: structural analysis of glycoprotein oligosaccharides by mass spectrometry.  Arch Biochem Biophys. 1983;  224(1) 127-133
    CrossrefPubMedGoogle Scholar
  • 31 Schoenecker J G, Hauck R K, Mercer M C, Parker W, Lawson J H. Exposure to topical bovine thrombin during surgery elicits a response against the xenogeneic carbohydrate galactose alpha1-3galactose.  J Clin Immunol. 2000;  20(6) 434-444
    CrossrefPubMedGoogle Scholar
  • 32 Lomax C. Safety of topical thrombins: the ongoing debate.  Patient Saf Surg. 2009;  3(1) 21
    CrossrefPubMedGoogle Scholar
  • 33 Terrab A, Pawlak D, Spaay P, Hoppensteadt D, Fareed J. Further removal of factor v related antigen from bovine thrombin by utilizing a membrane-filtration step.  , [see comment] Clin Appl Thromb Hemost. 2008;  14(2) 135-140
    CrossrefPubMedGoogle Scholar
  • 34 Zhu H, Hoppensteadt D, Wahi R et al.. Reduced immunogenic potential of membrane filtered bovine thrombin preparations for hemostatic application.  Clin Appl Thromb Hemost. 2009;  15(1) 32-40
    CrossrefPubMedGoogle Scholar
  • 35 Zhu H, Hoppensteadt D, Adiguzel C, Bick R L, Fareed J. Comparison of immunogenic potentials of bovine thrombin preparations.  Clin Appl Thromb Hemost. 2009;  15(1) 41-49
    CrossrefPubMedGoogle Scholar
  • 36 Singla N K, Ballard J L, Moneta G, Randleman Jr C D, Renkens K L, Alexander W A. A phase 3b, open-label, single-group immunogenicity and safety study of topical recombinant thrombin in surgical hemostasis.  J Am Coll Surg. 2009;  209(1) 68-74
    CrossrefPubMedGoogle Scholar
  • 37 Physicians' Desk Reference .Red Book 2009. Montvale, NJ; Physicians' Desk Reference 2009
    PubMedGoogle Scholar

William C ChapmanM.D. 

Professor and Chief, Division of General Surgery and Section of Abdominal Transplantation, Washington University in St. Louis

660 South Euclid, Box 8109, St. Louis, MO 63110

Email: chapmanw@wustl.edu